BOSTON — Trial results show patiromer is effective in controlling hyperkalemia and helps to reduce the risk of using blood pressure medications in patients with chronic kidney disease and heart failure.
“Renin-angiotensin-aldosterone system inhibitors (RAASi) are the cornerstone of treatment for both heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease,” Matthew R. Weir, MD, of the University of Maryland, and colleagues wrote in a late-breaking abstract presented at the National Kidney Foundation Spring Clinical Meetings. “Despite guidelines